PROFILBARU.COM

Deuruxolitinib
Clinical data
Trade names	Leqselvi
Other names	CTP-543
AHFS/Drugs.com	Leqselvi
License data	US DailyMed: Deuruxolitinib;
Routes of; administration	By mouth
Drug class	Janus kinase inhibitor
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (3R)-3-(2,2,3,3,4,4,5,5-Octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;
CAS Number	1513883-39-0; as phosphate: 2147706-60-1;
PubChem CID	72704611; as phosphate: 154572727;
DrugBank	DB18847;
ChemSpider	115010950;
UNII	0CA0VSF91Y; as phosphate: 8VJ43S4LCM;
KEGG	D11866; as phosphate: D11867;
ChEMBL	ChEMBL4594381;
Chemical and physical data
Formula	C17H18N6
Molar mass	306.373 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H];
	InChI InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2; Key:HFNKQEVNSGCOJV-FBXGHSCESA-N; Key:JFMWPOCYMYGEDM-NTVOUFPTSA-N;

Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.^[1] It is a Janus kinase inhibitor selective for JAK1 and JAK2.^[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.^[3]

Deuruxolitinib was approved for medical use in the United States in July 2024.^[1]^[4]^[5]

Medical uses

Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.^[1]

Side effects

The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.^[6]

Society and culture

Names

Deuruxolitinib is the international nonproprietary name^[7] and the United States Adopted Name.^[8]

References

^ ^a ^b ^c ^d "Archived copy" (PDF). Archived (PDF) from the original on 29 July 2024. Retrieved 26 July 2024.{{cite web}}: CS1 maint: archived copy as title (link)
^ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.
^ SEDEH, Farnam Barati; MICHAELSDÓTTIR, Thorunn Elísabet; HENNING, Mattias Arvid Simon; JEMEC, Gregor Borut Ernst; IBLER, Kristina Sophie (25 January 2023). "Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis". Acta Dermato-Venereologica. 103: 4536. doi:10.2340/actadv.v103.4536. ISSN 0001-5555. PMC 10391778. PMID 36695751.
^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
^ "U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata" (Press release). Sun Pharmaceutical. 25 July 2024. Archived from the original on 26 July 2024. Retrieved 26 July 2024 – via PR Newswire.
^ http://www.leqselvi.com/&a=Prescribing Information
^ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl:10665/346562.
^ "Deuruxolitinib". American Medical Association. Retrieved 27 July 2024.

External links

"Deuruxolitinib (Code C175770)". NCI Thesaurus.
"Deuruxolitinib Phosphate (Code C175771)". NCI Thesaurus.
Clinical trial number NCT04518995 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)" at ClinicalTrials.gov
Clinical trial number NCT04797650 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[FDA_approval_letter-1] "Archived copy" (PDF). Archived (PDF) from the original on 29 July 2024. Retrieved 26 July 2024.{{cite web}}: CS1 maint: archived copy as title (link)

[2] King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.

[3] SEDEH, Farnam Barati; MICHAELSDÓTTIR, Thorunn Elísabet; HENNING, Mattias Arvid Simon; JEMEC, Gregor Borut Ernst; IBLER, Kristina Sophie (25 January 2023). "Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis". Acta Dermato-Venereologica. 103: 4536. doi:10.2340/actadv.v103.4536. ISSN 0001-5555. PMC 10391778. PMID 36695751.

[Novel_Drug_Approvals_for_2024-4] "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.

[5] "U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata" (Press release). Sun Pharmaceutical. 25 July 2024. Archived from the original on 26 July 2024. Retrieved 26 July 2024 – via PR Newswire.

[Leqselvi_FDA_label-6] ttp://www.leqselvi.com/&a=Prescribing Information

[7] World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl:10665/346562.

[8] "Deuruxolitinib". American Medical Association. Retrieved 27 July 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Deuruxolitinib